Furthermore, in drug prediction of patients with different TGFβ subgroups, it was found that patients in the high TGFβ group were less sensitive to treatment with small molecule compounds, which may be related to the increased extracellular interstitial component of gastric cancer induced by high TGFβ levels. This evidence concerns the gene TGFB1 and gastric cancer.